An oral formulation of Angiotensin-(1-7) reverses corpus cavernosum damages induced by Hypercholesterolemia

Journal of Sexual Medicine

Volumn 10, Issue 10, 2013, Pages 2430-2442

  Fraga Silva, Rodrigo A ^a   Costa Fraga, Fabiana P ^a   Savergnini, Silvia Q ^a   De Sousa, Frederico B ^b   Montecucco, Fabrizio ^c   da Silva, Daniele ^a   Sinisterra, Ruben D ^b   Mach, François ^c   Stergiopulos, Nikolaos ^a   da Silva, Rafaela F ^a,b   Santos, Robson A S ^b  

^a EPFL   (Switzerland)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Angiotensin (1 7); Erectile Dysfunction; Fibrosis; Hydroxypropyl Cyclodextrin; Hypercholesterolemia; Mas Receptor; Oxidative Stress

Indexed keywords

ANGIOTENSIN; APOLIPOPROTEIN E; COLLAGEN; CYCLODEXTRIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROETHIDINE; NEURONAL NITRIC OXIDE SYNTHASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; CORPUS CAVERNOSUM; CORPUS CAVERNOSUM DAMAGE; DIET; HYPERCHOLESTEROLEMIA; LONG TERM CARE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PENILE FIBROSIS; PENIS INJURY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; WESTERN BLOTTING;

ANGIOTENSIN-(1-7); ERECTILE DYSFUNCTION; FIBROSIS; HYDROXYPROPYL-CYCLODEXTRIN; HYPERCHOLESTEROLEMIA; MAS RECEPTOR; OXIDATIVE STRESS;

ADMINISTRATION, ORAL; ANGIOTENSIN I; ANIMALS; APOLIPOPROTEINS E; COLLAGEN; CYCLODEXTRINS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FIBROSIS; HYPERCHOLESTEROLEMIA; IMPOTENCE, VASCULOGENIC; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PENILE ERECTION; PENIS; PEPTIDE FRAGMENTS; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS; REACTIVE OXYGEN SPECIES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, G-PROTEIN-COUPLED; VASODILATION; VASODILATOR AGENTS;

EID: 84885901551     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12262     Document Type: Article

References (46)

1. Musicki B, Liu T, Lagoda GA, Strong TD, Sezen SF, Johnson JM, Burnett AL. Hypercholesterolemia-induced erectile dysfunction: Endothelial nitric oxide synthase (eNOS) uncoupling in the mouse penis by NAD(P)H oxidase. J Sex Med 2010;7:3023-3032.
2. Kim JH, Klyachkin ML, Svendsen E, Davies MG, Hagen PO, Carson CC 3rd. Experimental hypercholesterolemia in rabbits induces cavernosal atherosclerosis with endothelial and smooth muscle cell dysfunction. J Urol 1994;151:198-205.
3. Bivalacqua TJ, Usta MF, Champion HC, Kadowitz PJ, Hellstrom WJ. Endothelial dysfunction in erectile dysfunction: Role of the endothelium in erectile physiology and disease. J Androl 2003;24(6 suppl):S17-37.
4. Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am 2005;32:379-395, v.
5. Xie D, Odronic SI, Wu F, Pippen AM, Donatucci CF, Annex BH. A mouse model of hypercholesterolemia-induced erectile dysfunction. J Sex Med 2007;4(4 Pt 1):898-907.
6. Kim SC, Kim IK, Seo KK, Baek KJ, Lee MY. Involvement of superoxide radical in the impaired endothelium-dependent relaxation of cavernous smooth muscle in hypercholesterolemic rabbits. Urol Res 1997;25:341-346.
7. Azadzoi KM, Saenz de Tejada I. Hypercholesterolemia impairs endothelium-dependent relaxation of rabbit corpus cavernosum smooth muscle. J Urol 1991;146:238-240.
8. Nehra A, Azadzoi KM, Moreland RB, Pabby A, Siroky MB, Krane RJ, Goldstein I, Udelson D. Cavernosal expandability is an erectile tissue mechanical property which predicts trabecular histology in an animal model of vasculogenic erectile dysfunction. J Urol 1998;159:2229-2236.
9. Yesilli C, Yaman O, Anafarta K. Effect of experimental hypercholesterolemia on cavernosal structures. Urology 2001;57:1184-1188.
10. Musicki B, Liu T, Sezen SF, Burnett AL. Targeting NADPH oxidase decreases oxidative stress in the transgenic sickle cell mouse penis. J Sex Med 2012;9:1980-1987.
11. Becker AJ, Uckert S, Stief CG, Truss MC, Machtens S, Scheller F, Knapp WH, Hartmann U, Jonas U. Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescence. Urology 2001;57:193-198.
12. Park JK, Kim SZ, Kim SH, Park YK, Cho KW. Renin angiotensin system in rabbit corpus cavernosum: Functional characterization of angiotensin II receptors. J Urol 1997;158:653-658.
13. Kifor I, Williams GH, Vickers MA, Sullivan MP, Jodbert P, Dluhy RG. Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol 1997;157:1920-1925.
14. Becker AJ, Uckert S, Stief CG, Scheller F, Knapp WH, Hartmann U, Jonas U. Plasma levels of angiotensin II during different penile conditions in the cavernous and systemic blood of healthy men and patients with erectile dysfunction. Urology 2001;58:805-810.
15. Ferreira AJ, Santos RA. Cardiovascular actions of angiotensin-(1-7). Braz J Med Biol Res 2005;38:499-507.
16. Ferreira AJ, Santos RA, Bradford CN, Mecca AP, Sumners C, Katovich MJ, Raizada MK. Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension 2010;55:207-213.
17. Bader M, Ganten D. Update on tissue renin-angiotensin systems. J Mol Med 2008;86:615-621.
18. da Costa Goncalves AC, Leite R, Fraga-Silva RA, Pinheiro SV, Reis AB, Reis FM, Touyz RM, Webb RC, Alenina N, Bader M, Santos RA. Evidence that the vasodilator angiotensin-(1-7)-Mas axis plays an important role in erectile function. Am J Physiol Heart Circ Physiol 2007;293:H2588-2596.
19. Yousif MH, Kehinde EO, Benter IF. Different responses to angiotensin-(1-7) in young, aged and diabetic rabbit corpus cavernosum. Pharmacol Res 2007;56:209-216.
20. Ferreira AJ, Murca TM, Fraga-Silva RA, Castro CH, Raizada MK, Santos RA. New cardiovascular and pulmonary therapeutic strategies based on the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis. Int J Hypertens 2012;2012:147825.
21. Yamada K, Iyer SN, Chappell MC, Ganten D, Ferrario CM. Converting enzyme determines plasma clearance of angiotensin-(1-7). Hypertension 1998;32:496-502.
22. Lula I, Denadai AL, Resende JM, de Sousa FB, de Lima GF, Pilo-Veloso D, Heine T, Duarte HA, Santos RA, Sinisterra RD. Study of angiotensin-(1-7) vasoactive peptide and its beta-cyclodextrin inclusion complexes: Complete sequence-specific NMR assignments and structural studies. Peptides 2007;28:2199-2210.
23. Uekama K. Design and evaluation of cyclodextrin-based drug formulation. Chem Pharm Bull (Tokyo) 2004;52:900-915.
24. Fraga-Silva RA, Costa-Fraga FP, De Sousa FB, Alenina N, Bader M, Sinisterra RD, Santos RA. An orally active formulation of angiotensin-(1-7) produces an antithrombotic effect. Clinics 2011;66:837-841.
25. Marques FD, Melo MB, Souza LE, Irigoyen MC, Sinisterra RD, de Sousa FB, Savergnini SQ, Braga VB, Ferreira AJ, Santos RA. Beneficial effects of long-term administration of an oral formulation of angiotensin-(1-7) in infarcted rats. Int J Hypertens 2012;2012:1-12.
26. Marques FD, Ferreira AJ, Sinisterra RD, Jacoby BA, Sousa FB, Caliari MV, Silva GA, Melo MB, Nadu AP, Souza LE, Irigoyen MC, Almeida AP, Santos RA. An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats. Hypertension 2011;57:477-483.
27. Nunes KP, Wynne BM, Cordeiro MN, Borges MH, Richardson M, Leite R, DeLima ME, Webb RC. Increased cavernosal relaxation by Phoneutria nigriventer toxin, PnTx2-6, via activation at NO/cGMP signaling. Int J Impot Res 2012;24:69-76.
28. Schlimmer N, Kratz M, Bohm M, Baumhakel M. Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosis. Br J Pharmacol 2011;163:804-814.
29. Baumhakel M, Custodis F, Schlimmer N, Laufs U, Bohm M. Improvement of endothelial function of the corpus cavernosum in apolipoprotein E knockout mice treated with irbesartan. J Pharmacol Exp Ther 2008;327:692-698.
30. Suresh S, Prakash S. Effect of Mucuna pruriens (Linn.) on oxidative stress-induced structural alteration of corpus cavernosum in streptozotocin-induced diabetic rat. J Sex Med 2011;8:1943-1956.
31. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH. Nitric oxide: A physiologic mediator of penile erection. Science 1992;257:401-403.
32. Chung E, De Young L, Brock GB. Investigative models in erectile dysfunction: A state-of-the-art review of current animal models. J Sex Med 2011;8:3291-3305.
33. Touyz RM. Reactive oxygen species and angiotensin II signaling in vascular cells-Implications in cardiovascular disease. Braz J Med Biol Res 2004;37:1263-1273.
34. Nishiyama A, Fukui T, Fujisawa Y, Rahman M, Tian RX, Kimura S, Abe Y. Systemic and regional hemodynamic responses to tempol in angiotensin II-infused hypertensive rats. Hypertension 2001;37:77-83.
35. Wilson SK. Role of oxygen-derived free radicals in acute angiotensin II-Induced hypertensive vascular disease in the rat. Circ Res 1990;66:722-734.
36. Rabelo LA, Alenina N, Bader M. ACE2-angiotensin-(1-7)-Mas axis and oxidative stress in cardiovascular disease. Hypertens Res 2011;34:154-160.
37. Grobe JL, Mecca AP, Mao H, Katovich MJ. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol 2006;290:H2417-2423.
38. Deelman L, Sharma K. Mechanisms of kidney fibrosis and the role of antifibrotic therapies. Curr Opin Nephrol Hypertens 2009;18:85-90.
39. Zhang J, Noble NA, Border WA, Huang Y. Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. Am J Physiol Renal Physiol 2010;298:F579-588.
40. Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva RA, Diez-Freire C, Dooies A, Jun JY, Sriramula S, Mariappan N, Pourang D, Venugopal CS, Francis J, Reudelhuber T, Santos RA, Patel JM, Raizada MK, Katovich MJ. The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2010;182:1065-1072.
41. Pereira RM, Dos Santos RA, Teixeira MM, Leite VH, Costa LP, da Costa Dias FL, Barcelos LS, Collares GB, Simoes Silva AC. The renin-angiotensin system in a rat model of hepatic fibrosis: Evidence for a protective role of angiotensin-(1-7). J Hepatol 2007;46:674-681.
42. Ferreira AJ, Shenoy V, Qi Y, Fraga-Silva RA, Santos RA, Katovich MJ, Raizada MK. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol 2011;96:287-294.
43. McCollum LT, Gallagher PE, Ann Tallant E. Angiotensin-(1-7) attenuates angiotensin II-induced cardiac remodel ing associated with upregulation of dual-specificity phosphatase 1. Am J Physiol Heart Circ Physiol 2012;302:H801-810.
44. Pei Z, Meng R, Li G, Yan G, Xu C, Zhuang Z, Ren J, Wu Z. Angiotensin-(1-7) ameliorates myocardial remodeling and interstitial fibrosis in spontaneous hypertension: Role of MMPs/TIMPs. Toxicol Lett 2010;199:173-181.
45. Katovich MJ, Grobe JL, Raizada MK. Angiotensin-(1-7) as an antihypertensive, antifibrotic target. Curr Hypertens Rep 2008;10:227-232.
46. Xu P, Costa-Goncalves AC, Todiras M, Rabelo LA, Sampaio WO, Moura MM, Santos SS, Luft FC, Bader M, Gross V, Alenina N, Santos RA. Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice. Hypertension 2008;51:574-580.